BioCentury | May 30, 2016
Clinical News

STM 434: Preliminary Phase I data

...U.S. Phase I trial showed that 0.25, 0.5, 0.75 and 1 mg/kg doses of IV STM 434...
...and there was 1 dose-limiting toxicity (DLT) of self-limited peritoneal bleeding at the 0.5 mg/kg STM 434...
...expansion portion in patients with advanced granulosa cell ovarian cancer; and part 3 will evaluate STM 434...
BioCentury | Dec 15, 2015
Clinical News

Atara looks to pipeline after Phase II failure

...cytomegalovirus (CMV) infections. The company's Phase I candidates include WT1-CTL to treat hematologic malignancies and STM 434...
...consist of cytotoxic T lymphocytes specific to EBV, CMV and Wilms tumor 1 , respectively. STM 434...
BioCentury | Nov 10, 2014
Clinical News

STM 434: Phase I started

...Atara began an open-label, dose-escalation, U.S. Phase I trial to evaluate 0.25-4 mg/kg IV STM 434 every...
...trial will determine the maximum tolerated dose (MTD) in patients with solid tumors and test STM 434...
...IV liposomal doxorubicin in patients with ovarian cancer. Atara Biotherapeutics Inc. (NASDAQ:ATRA), Brisbane, Calif. Product: STM 434...
BioCentury | Dec 18, 2013
Financial News

Atara secures $38.5 million in series B

...with end-stage renal disease (ESRD). Data are expected by the end of 2014. The company's STM 434...
Items per page:
1 - 4 of 4